BioCentury
ARTICLE | Company News

Metacrine partners with Novo Nordisk to develop FGF1 variants

August 18, 2017 4:29 PM UTC

Metacrine Inc. (San Diego, Calif.) partnered with Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) to develop fibroblast growth factor 1 (FGF1) variants for glucose lowering and insulin sensitization.

Metacrine said it has developed a large library of FGF1 variants with improved "pharmaceutical properties." Under the deal, the biotech will continue to develop and characterize FGF1 variants. Novo will have an option to license the FGF1 program after undisclosed research milestones are met...